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Ultrasound-sensitive (sonosensitive) liposomes for tumor targeting have been studied in order to increase the
antitumor efficacy of drugs and decrease the associated severe side effects. Liposomal contrast agents having Gd(III)
are known as a nano-contrast agent system for the efficient and selective delivery of contrast agents into
pathological sites. The objective of this study was to prepare Gd(III)-DOTA-modified sonosensitive liposomes (GdSL),
which could deliver a model drug, doxorubicin (DOX), to a specific site and, at the same time, be capable of
magnetic resonance (MR) imaging. The GdSL was prepared using synthesized Gd(III)-DOTA-1,2-distearoyl-sn-glycero-
3-phosphoethanolamine lipid. Sonosensitivity of GdSL to 20-kHz ultrasound induced 33% to 40% of DOX release.
The relaxivities (r1) of GdSL were 6.6 to 7.8 mM
−1 s−1, which were higher than that of MR-besterW. Intracellular
uptake properties of GdSL were evaluated according to the intensity of ultrasound. Intracellular uptake of DOX for
ultrasound-triggered GdSL was higher than that for non-ultrasound-triggered GdSL. The results of our study suggest
that the paramagnetic and sonosensitive liposomes, GdSL, may provide a versatile platform for molecular imaging
and targeted drug delivery.
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Liposomes are spherical vesicles composed of phospho-
lipid bilayer membranes. In the field of targeted drug
delivery, liposomes have been extensively studied in an
attempt to enhance the therapeutic efficacy of various
drugs [1,2]. Many studies have reported that modifica-
tion of the surface of liposomes with a hydrophilic
moiety such as polyethylene glycol (PEG) can increase
the circulation time of the liposomes in the bloodstream
due to reduced uptake of the liposomes by the reticu-
loendothelial system (RES) [3-7]. However, utilization of
liposomes as drug-carrying vehicles for intracellular
delivery of anticancer drugs loaded in the liposomes is
limited due to the lack of specific interaction between
liposomal carriers and the target cells [8]. Therefore, to
overcome this problem, targeted drug delivery systems
such as thermo-, pH-, ultrasound-, and optical-sensitive
liposomes have been studied [9,10]. In particular,* Correspondence: bcshin@krict.re.kr
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in any medium, provided the original work is pultrasound-sensitive (sonosensitive) liposomes for con-
trolled drug release at the target site have been studied
in order to increase the antitumor efficacy of drugs and
decrease the associated side effects [11,12].
Magnetic resonance (MR) is widely used in diagnos-
tic medicine to image pathological areas. Usually, accu-
mulation of contrast agents is essential to achieve
successful MR imaging (MRI) and high-resolution
images [13,14]. Most MRI contrast agents are based
on either iron oxide particle or gadolinium (III)
(Gd(III))-chelated complexes. Gd(III)-based contrast
agents have a low r2/r1 ratio and are frequently used
to generate positive contrast (increased signal intensity)
in T1-weighted images. Recently, various nanoscale car-
riers such as liposomes, micelles, and polymeric nano-
particles have been modified or incorporated with the
MRI contrast agent Gd(III) [14,15]. Liposomal nano-
carriers are able to carry multiple reporter moieties
such as peptides and antibodies for the efficient and
selective delivery of contrast agents into the patho-
logical sites [16].
The objective of this study was to develop a novel lipo-
somal carrier that could provide a convenient ultrasonicOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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sound therapy, by MR image guidance and, moreover, a
possibility of ultrasound-mediated targeted drug delivery
during ultrasonic therapy. In the current study, we pre-
pared Gd(III)-DOTA-modified sonosensitive liposomes
(GdSL), which could deliver doxorubicin (DOX) to a
specific site and, at the same time, enhance signal inten-
sity in regions of accumulation on T1-weighted MRI.
The GdSL was prepared using synthesized Gd(III)-
DOTA-1,2-distearoyl-sn-glycero-3-phosphoethanolamine
(DSPE) lipid. Sonosensitivity and MR properties of
the GdSLs with varying lipid ratios were investi-
gated. Furthermore, intracellular uptake property of






glycol)-2000] (DSPE-mPEG2000), and cholesterol (CHOL)
were purchased from Avanti Polar Lipids Inc. (Alabaster,
AL, USA). DoxilW was purchased from ALZA Corporation
(Mountain View, CA, USA). Doxorubicin hydrochloride,
N,N′-diisopropylethylamine (DiPEA), N,N,N′,N′-tetramethyl-
O-(N-succinimidyl) uranium hexafluorophosphate (HSTU),
trifluoroacetic acid (TFA), and gadolinium (III) acetate
hydrate (Gd(III) (OAc)3) were purchased from Sigma-
Aldrich Chemical Co (St. Louis, MO, USA). Fetal bovine
serum (FBS), penicillin-streptomycin, paraformaldehyde,
and Dulbecco's modified Eagle medium (DMEM) were
purchased from Gibco BRL/Life Technologies (New York,
NY, USA). Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetate (protected DOTA) was purchased
from Tokyo Chemical Industry Corporation (TCI, Tokyo,
Japan). All other materials were of analytical grade and used
without further purification.
Synthesis of Gd(III)-DOTA-DSPE
Gd(III)-DOTA-DSPE was synthesized as shown in Figure 1
[17-19]. Protected DOTA (0.9 mmol) was added to 5 ml of
dry dimethylformamide containing 0.9 mmol of HSTU
and 3.2 mmol of DiPEA under a nitrogen atmosphere, and
the mixture was stirred for 1 h at room temperature. The
obtained solution was added to 10 ml of chloroform
containing 0.8 mmol of DSPE, stirred for 3 h at 65°C,
and incubated overnight at room temperature. After
evaporation of the solution with toluene (2 × 20 ml) and
chloroform (2 × 20 ml) using a rotary evaporator (Buchi
Rotavapor R-200, Flawil, Switzerland), the product was
precipitated in water/methanol (1:1 v/v), and the precipi-
tate was isolated by centrifugation. The resulting pellet was
dissolved in chloroform, and the solution was concentrated
under vacuum. The resulting solid was redissolved in20 ml of diethyl ether and washed with water (2 × 10 ml).
The organic phase was collected and concentrated in
vacuum to obtain powder. The prepared powder was dis-
solved in 10 ml of TFA/chloroform (3:7, v/v) and stirred
for 17 h at room temperature. The solution was evaporated
with toluene (2×20 ml) and chloroform (2× 20 ml) using
a rotary evaporator, precipitated in acetonitrile, and dried
under vacuum. A solution of the yellowish solid in 9 ml of
chloroform was mixed with a solution of 0.42 mmol
Gd(III) (OAc)3 in 5 ml of methanol/water (10:1, v/v),
adjusted to pH 6.5 with pyridine, and stirred overnight at
room temperature. The solution was concentrated under
reduced pressure and co-evaporated with methanol/
toluene (1:1, v/v, 2 ×10 ml) and chloroform (2×10 ml),
resulting in Gd(III)-DOTA-DSPE as a yellowish solid. The
yield of Gd(III)-chelated Gd(III)-DOTA-DSPE was 80%. Gd
(III)-DOTA-DSPE, 1H-NMR (CDCl3): δ=7.73 (s, 1 H, NH),
4.24 (m, 1 H, CH), 2.34 (m, 4 H, CH3(CH2)15CH2CO), 1.27
(m, 60 H), 0.91 (t, 6 H, (CH2)15CH3), and MALDI-TOF
(negative mode): m/z [M-H−], calculated=1,287.1 Da.,
observed=1,287.2 Da.Preparation of Gd(III)-DOTA-modified sonosensitive
liposomes
Gd(III)-DOTA-modified sonosensitive liposomes (GdSL)
and sonosensitive liposomes (SL) without Gd(III)-DOTA-
DSPE were prepared by thin-film hydration and sequential
extrusion method. The loading of DOX into the aqueous
core of the liposomes was carried out using the remote
loading method using an ammonium sulfate transmem-
brane gradient [20,21]. The lipid compositions and molar
ratios of the lipids for the preparation of the liposomes
were as follows: (1) GdSL1, Gd(III)-DOTA-DSPE/CHOL/
DSPE-mPEG=31:15:4; (2) GdSL2, Gd(III)-DOTA-DSPE/
CHOL/DSPE-mPEG/DSPE=20:15:4:11; (3) GdSL3, Gd
(III)-DOTA-DSPE/CHOL/DSPE-mPEG/DSPE=10:15:4:21;
and (4) SL, CHOL/DSPE-mPEG/DSPE=15:4:31. The
lipids for each liposome formulation were dissolved in
3 ml of chloroform to give 16.67 mM of total lipid
concentration (GdSL1, 18.97 mg/ml; GdSL2, 16.97 mg/ml;
GdSL3, 15.17 mg/ml; and SL, 13.41 mg/ml) and dried to a
thin film using a rotary evaporator. The film was hydrated
with 3 ml of 300 mM ammonium sulfate solution, and the
liposome suspension was extruded sequentially five times
through polycarbonate membrane filters (Whatman,
Piscataway, NJ, USA) with a pore size of 200 and
100 nm using a high-pressure extruder (Northern Lipids
Inc., Burnaby, Canada). Unloaded ammonium sulfate
was removed by dialysis in distilled water for 24 h at 4°C
using a cellulose dialysis tube (MWCO, 12,000 to 14,000;
Viskase Co., Darien, IL, USA). DOX solution (2 mg/ml)
was added to the liposomal solution (1:1, v/v) and incu-
bated for 2 h at 75°C. The mixture was dialyzed for 48 h at
Figure 1 Synthesis of Gd(III)-DOTA-DSPE for the preparation of GdSLs.
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liposomes were stored at 4°C until use.
The concentration of DOX in the liposomes was
measured using a UV-vis spectrophotometer at 497
nm (UV-mini; Shimadzu, Tokyo, Japan), and theencapsulation efficiency was calculated according to the
following equation:
Encapsulation efficiency %ð Þ ¼ Ft
Fi
 100 ð1Þ
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after the dissolution of DOX-loaded liposomes in an
organic solvent mixture consisting of chloroform/
methanol (2:1, v/v), and Fi is the initial concentration of
DOX. The particle size and zeta potential of the lipo-
somes were measured using an electrophoretic light
scattering spectrophotometer (ELS-Z, Otuska Electronics
Co., Tokyo, Japan). The amount of chelated Gd(III) was
measured using an inductively coupled plasma-atomic
emission spectrometer (Ultima-C, Jobin Yvon, Longju-
meau, France).
Ultrasound- and temperature-triggered drug release from
liposomes
Ultrasound-triggered release of DOX from GdSL and SL
was conducted using a 20-kHz ultrasound system (VC
750; Sonic and Materials, Inc, Newtown, CT, USA). The
intensity of the generated ultrasound was determined
using a calorimetric method [22,23]. For input power
levels of 80, 160, and 240 W, the calculated intensity
levels were 14.8, 27.8, and 63.5 W/cm2, respectively. The
liposomal solutions were diluted in a ratio of 1:4 (v/v)
with PBS (pH 7.4) and exposed to a continuous mode
(100% duty cycle) of ultrasound for 1 min at intensity
levels of 14.8, 27.8, and 63.5 W/cm2, respectively. During
the ultrasound irradiation, the temperature of each sam-
ple was controlled to be below 50°C. Temperature-
mediated release from GdSL was evaluated using
MULTI-BLOK (Lab-Line Instruments, Melrose Park, IL,
USA). The liposomal solutions were exposed to 37°C or
50°C for 1 min.
The release of DOX from liposomes was measured by
fluorescence spectrophotometry. The excitation and
emission wavelengths were 487 and 595 nm, respect-
ively. The percentage of DOX release from the lipo-
somes was calculated as follows:
Drug release %ð Þ ¼ Ft  F0ð Þ
Fmax  F0ð Þ  100 ð2Þ
where Ft is the fluorescence intensity of the liposome
sample after a given duration (t) of ultrasound irradi-
ation, F0 is the initial background fluorescence of the
liposome sample prior to ultrasound irradiation, and
Fmax is the fluorescence intensity of DOX in the lipo-
somes after dissolution of DOX-loaded liposomes in an
organic solvent mixture consisting of chloroform/methanol
(2:1, v/v) [24]. The release test was performed on three
independent samples of each liposome.
Morphology of Gd(III)-DOTA-modified sonosensitive
liposomes
The morphology of GdSL was observed by cryogenic
transmission electron microscopy (cryo-TEM; TecnaiG2 Spirit, FEI Company, Hillsboro, OR, USA). Samples
for the cryo-TEM observation were prepared using a
controlled-environment vitrification system. Five micro-
liters of the sample were put on a carbon film supported
by a copper grid and blotted with filter papers to obtain
a thin liquid film on the grid. The sample-loaded grid
was quenched in liquid ethane at −180°C and transferred
to liquid nitrogen. The acceleration voltage was 80 kV,
and the working temperature was −180°C. The images
were recorded with a CCD camera (Proscan GmbH,
Scheuring, Germany) and an analysis software (Soft Im-
aging System, GmbH, Munster, Germany) [25].
Relaxivity measurement
The liposomal samples were prepared in the range of 0.05
to 0.40 mM of Gd(III) concentration. The longitudinal
relaxation time (T1) of each sample was measured by
saturation recovery method using a 4.7-T MR system
(Bruker-biospin, Ettlingen, Germany). Relaxivity (r1, in
units of mM−1 s−1) was obtained from the slope of the lin-
ear fit of the inverse of T1 as a function of Gd(III) con-
centration. T1-weighted MR images were obtained
using a heavily T1-weighted fast spoiled gradient echo
sequence. Scans were performed with the following im-
aging parameters: repetition time (TR) = 8.0, 6.0, 4.0,
2.5, 0.5, 0.2, and 0.07 s; echo time (TE)= 7.8 ms; flip angle
(FA)=180°; field of view (FOV)=40×50 mm2; image
matrix = 128×128 mm2; and number of signal average=5.
Intracellular uptake of DOX from ultrasound-triggered
liposomes
For the experiments on intracellular uptake of DOX
from liposomes, B16F10 murine melanoma cells were
cultured in DMEM supplemented with 10% (v/v) heat-
inactivated FBS and 10 μl/ml penicillin-streptomycin.
The cultures were sustained at 37°C in a humidified
incubator containing 5% CO2. The cells were main-
tained within their exponential growth phase. The
intracellular uptake of DOX from liposomes was deter-
mined by flow cytometry analysis [24,26]. B16F10 cells
were transferred to 24-well tissue culture plates at a
density of 1 × 105 cells/well and incubated for 12 h at
37°C. The liposomal DOX solutions were diluted in a
ratio of 1:4 (v/v) with PBS (pH 7.4) just prior to the
experiments. The diluted liposomal solutions were irra-
diated by ultrasound using a 20-kHz ultrasound trans-
ducer in a continuous mode (100% duty cycle) at an
intensity level of 14.8, 27.8, or 63.5 W/cm2 for 2 min
at 37°C. The culture medium was replaced with the
ultrasonically irradiated liposomal DOX solution
diluted in culture media at a concentration of 15 μg of
DOX/ml and then incubated for 45 min. The culture
medium was then removed, and each well was washed
with PBS (pH 7.4). To fix the cells, 300 μl of
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The fluorescence intensities of the sample were deter-
mined by flow cytometry with a FACScan (Becton
Dickinson, San Jose, CA, USA). Cell-associated DOX
was excited with an argon laser (488 nm), and fluores-
cence was detected at 560 nm. Data of 10,000 gated
events were collected and analyzed with the CELL
Quest software.
Results and discussion
Physical properties of liposomes
The physical properties of various GdSLs and SL were
evaluated by measuring their mean particle diameter,
zeta potential, DOX-loading efficiency, and amount of
Gd(III), as summarized in Table 1. The mean particle
diameter of SL was approximately 129 nm, and the par-
ticle diameter of GdSL was increased according to the
amount of Gd(III)-DOTA-DSPE in the lipid bilayer of
the liposome. The zeta potential value of the liposomes
was approximately −20 to −30 mV due to the PEG and
the Gd(III)-DOTA complex having lone pairs of oxygen
atom electrons. DSPE-mPEG2000 incorporated in pegy-
lated liposomes is known to inhibit opsonization and
RES uptake of the liposomes by forming hydrodynamic
layer on them and hence prolong circulation time of the
encapsulated drugs in the bloodstream [27]. CHOL in
liposome plays a role in increasing the stability of the
liposome. It was reported that incorporation of CHOL
to drug-carrying vehicles such as liposomes could
increase their stability in the bloodstream [28]. The
amount of Gd(III) in GdSLs was proportional to the
increase of Gd(III)-DOTA-DSPE content in the lipid
composition. The Gd(III)-DOTA-DSPE was used as a
lipid having magnetic resonance effect for contrast
agents. Recently, it was reported that DSPE as the main
lipid component could enhance sonosensitivy of the
liposomes [29]. Therefore, DSPE was herein used as a
sonosensitive lipid. The DOX-loading efficiency of GdSLsTable 1 Physical properties of liposomes
Liposome formulation Mean particle d
(molar ratio of lipids) (nm)
GdSL1 157.1 ± 8
Gd(III)-DOTA-DSPE/CHOL/DSPE-mPEG2000= 31:15:4)
GdSL2 156.4 ± 5
Gd(III)-DOTA-DSPE/CHOL/DSPE-mPEG2000/DSPE= 20:15:4:11)
GdSL3 131.4 ± 9
Gd(III)-DOTA-DSPE/CHOL/DSPE-mPEG2000/DSPE= 10:15:4:21)
SL 129.1 ± 6
(CHOL/DSPE-mPEG2000/DSPE = 15:4:31)
ND, not detected (amount of Gd(III) could not be measured because there is no Gdwas lower by approximately 35% to 56% than that of SL.
The Gd(III)-DOTA complex may induce steric effect and
mechanical stress in the membrane of lipid bilayers due to
the repulsive forces between the Gd(III)-DOTA complex
and PEG [11,30].Ultrasound- and temperature-triggered drug release from
liposomes
The release profile of DOX from GdSL and SL was inves-
tigated under various intensities (14.8, 27.8, and 63.5 W/
cm2) of 20-kHz ultrasound and temperatures (37°C and
50°C), as shown in Figure 2. The ultrasound-triggered
release of DOX from the liposomes was proportional to
the increase of DSPE mole ratio in the lipid composition
(Figure 2A). GdSL3 and SL showed a high DOX release
of 33% to 40% by ultrasound irradiation. Temperature-
dependent release of DOX from GdSL3 was not mea-
sured at 37°C and showed a release of approximately
3.2% at 50°C (Figure 2B). The results indicate that the
drug release from the sonosensitive liposomes, GdSL and
SL, could not be triggered at normal body temperature
but could be triggered mainly by cavitation.
Recently, Evjen et al. reported that sonosensitivity of
the liposomes is related to the ability of DSPE to form
inverted hexagonal structures under high temperature or
pressure [29]. Ultrasound irradiation-induced cavitations
can generate high pressure or temperature in the lipo-
some membrane [10,11]. Phase transitions of liposomes
have been known to be induced by pressure and/or
temperature changes. DSPE in the liposomal bilayer
undergoes a thermotropic phase transition from the
lamellar liquid-crystalline to the inverted hexagonal
phase by cavitation because the long fatty acids occupy
larger volume than the polar head groups [29,31]. The
phase transition might induce local defects or poly-
morphic phase transitions within micro-rafts or the whole
liposome bilayer during ultrasound irradiation, furtheriameterZeta potentialDOX-Encapsulation efficiencyAmount of Gd(III)
(mV) (%) (mM)
.9 −27.6 ± 4.2 46.6 ± 12.7 4.60 ± 0.16
.1 −21.9 ± 1.0 41.7 ± 9.7 3.17 ± 0.01
.1 −31.6 ± 7.2 62.9 ± 1.5 2.01 ± 0.31
.6 −31.9 ± 2.3 97.5 ± 0.4 ND
(III)).
Figure 2 Release pattern of DOX from GdSLs and SL. (A) The release of DOX from the liposomes after irradiation of 20-kHz ultrasound at
various intensities and (B) the release of DOX from the liposomes after incubation at 37°C or 50°C. Molar ratio of Gd(III)-DOTA-DSPE, CHOL, and
DSPE-mPEG2000 for GdSL1 was 31:15:4. Molar ratios of Gd(III)-DOTA-DSPE, CHOL, DSPE-mPEG2000, and DSPE for GdSL2 and GdSL3 were
20:15:4:11 and 10:15:4:21, respectively. Molar ratio of CHOL, DSPE-mPEG2000, and DSPE for SL was 15:4:31. All samples were treated for 1 min.
Mean and S.D. are shown (n= 3) (asterisk, two asterisks, and three asterisks denote p< 0.05, Student's t test).
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in Figure 3.
Morphology of ultrasound-irradiated liposomes
The morphology of GdSL3 observed by cryo-TEM is
shown in Figure 4. The majority of non-ultrasound-
irradiated GdSL3 was observed as a unilamellar liposome
structure having approximately 100 to 150 nm of particle(Figure 4A). The mean particle diameter of GdSL3
observed by cryo-TEM was similar to the value of
131.4 ± 9.1 nm analyzed by light scattering method using
a particle size analyzer (see Table 1). However,
ultrasound-irradiated GdSL3 was observed in the shape
of snapped liposomal membrane (>20%), as shown in
Figure 4B. The results indicate that ultrasound irradi-
ation could induce rupture of the liposomal membrane




Figure 4 Cryo-TEM images of (A) GdSL3 and (B) ultrasound-irradiated GdSL3. GdSL3 was irradiated by 20-kHz ultrasound for 5 min at an
intensity of 63.5 W/cm2. The arrows indicate the snapped liposomal membrane.
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as shown in Figure 3.
Magnetic resonance property of liposomes
MRI is one of the most powerful techniques currently
used in medical diagnostics such as tumor detection and
vascular imaging. Gd-based complexes, such as Gd(III)-
DOTA and Gd(III)-DTPA using paramagnetic material,
are known as the most effective T1 agents [16]. The MR
images of contrast agents are based on the same princi-
ples of nuclear magnetic resonance (NMR). The MR
image of contrast agents is related to the relaxation be-
havior of hydrogen nuclei of water. The principle mech-
anism for Gd(III)-complexes is due to the interaction ofFigure 5 Magnetic resonance properties of GdSLs. (A) T1-weighted MR
The MR images of SL were taken together for comparison. (B) Relaxivities (
obtained from the slope of the linear fit of the inverse of the measured T1
1/T1 data of SL without Gd(III)-DOTA-DSPE were presented as negative conan inner-sphere water molecule with the paramagnetic
Gd(III) ion having ninth coordination site, leading to the
subsequent magnetic relaxation of the water molecule
[32]. The signal intensity of the image is related to the
longitudinal relaxation time (T1), and a shortened T1
provides improved images [33].
Figure 5A shows T1-weighted MR images of GdSLs
and a commercial contrast agent, MR-besterW (Taejoon
Pharmaceuticals Co., Ltd., Seoul, Korea), at different con-
centrations of Gd(III) (0.4, 0.2, and 0.05 mM). The MR
images of various GdSLs showed similar brightness and
looked brighter compared to MR-besterW at the same
concentration of Gd(III). The brightness of MR imaging
of GdSL was proportional to the increase in Gd(III)images of GdSLs and MR-besterW at different concentrations of Gd(III).
r1, in units of mM
−1 s−1) of GdSLs and MR-besterW. Relaxivity was
(longitudinal relaxation time) as a function of Gd(III) concentration.
trols.
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because they did not contain Gd(III). The relaxivity (r1)
values of GdSLs were 6.57 to 7.83 mM−1 s−1, which was
approximately 5.0 to 6.0 times higher than that of MR-
besterW, as shown in Figure 4B. These results indicate
that GdSLs could induce strong relaxivity compared to
MR-besterW. Generally, Gd(III) complexes on the lipo-
somal surface are known to improve ionic relaxivity
compared to Gd(III)-entrapped liposomes [16]. The
NMR dispersion profiles of liposomal contrast agents
show a typical peak at higher frequencies [14,15]. This
is in agreement with the increase in the rotational correl-
ation times when compared with low molecular weight
Gd(III) complexes. Based on these results, GdSL3 was
selected as an optimized carrier for the cellular uptake
study because it showed high sonosensitivity and
relaxivity.
Intracellular uptake of DOX released from ultrasound-
triggered liposomes
To investigate the intracellular uptake of DOX released
from ultrasound-triggered liposomes, the amount of
accumulated DOX in B16F10 cells was measured by flow
cytometry. The results are shown in Figure 6. Intracellu-
lar uptake of DOX released from ultrasound-irradiated
GdSL3 was higher than that from GdSL3 or DoxilW. The
mean fluorescence intensity (MFI) values for ultrasound-
irradiated GdSL3 were approximately 3.7 to 5.4-fold
higher than that for GdSL3. The results indicate that the
triggered DOX release by ultrasound irradiation could









Figure 6 Intracellular uptake of DOX released from ultrasound-trigge
GdSL3-2, and GdSL3-3 were irradiated by 20-kHz ultrasound for 2 min at in
DOX, and DoxilW were not irradiated with ultrasound. Mean and S.D. are sh
Student's t test).liposomal DOX. Free DOX is known to enter cells by dif-
fusion, leading to high cellular uptake compared to the
liposomal DOX, and the liposomes modified with a
DOX-phospholipid conjugate can increase the cellular
uptake of DOX compared to the unmodified ones
[24,26]. GdSL3 and DoxilW exhibited low intracellular
uptake of DOX because GdSL3 and DoxilW with the an-
ionic surface charges could have electrostatic repulsion
with the cellular membrane. Ultrasound-irradiated
GdSL3 showed greater intracellular uptake of DOX be-
cause it induced the burst release of DOX by cavitation
in 1 min, as shown in Figure 2. Additionally, the intracel-
lular uptake of DOX according to the intensity of ultra-
sound showed a similar increase in intracellular uptake.Conclusions
Dual functional Gd(III)-DOTA-modified sonosensitive
liposomes were prepared and evaluated for their sonosen-
sitivity, MR properties, and in vitro intracellular uptake.
GdSL showed excellent contrast efficiency compared to a
commercial contrast agent, MR-besterW, and increased
intracellular uptake due to the ultrasound-triggered
release of the drug. Therefore, GdSL could deliver drugs
to specific sites by ultrasound irradiation and, at the same
time, allow MR imaging due to enhanced T1 relaxivity.
The results of our study suggest that the novel liposomal
carrier may provide a convenient ultrasonic therapy by
MR image guidance and, moreover, a possibility of
ultrasound-mediated targeted drug delivery during ultra-





red GdSL3. MFI was determined by flow cytometry analysis. GdSL3-1,
tensity levels of 14.8, 27.8, and 63.5 W/cm2, respectively. GdSL3, free
own (n= 3) (asterisk, two asterisks, and three asterisks denote p< 0.1,
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